The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
In conclusion, this meta-analysis showed a high clinical RR of CD19-CAR-T cell–based immunotherapy in patients with refractory B-cell malignancies.
Source: Cytotherapy - Category: Cytology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Cytology | Immunotherapy | Leukemia | Lymphoma | Study